{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:07:48Z","timestamp":1789927668365,"version":"4.0.1"},"reference-count":107,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Pediatric Neurology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.spen.2015.10.008","type":"journal-article","created":{"date-parts":[[2015,11,2]],"date-time":"2015-11-02T19:36:09Z","timestamp":1446492969000},"page":"240-258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms"],"prefix":"10.1016","volume":"22","author":[{"given":"Martino","family":"Ruggieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Domenico","family":"Pratic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dafydd Gareth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.spen.2015.10.008_bib1","series-title":"The Neurofibromatoses: A Pathogenetic and Clinical Overview","author":"Huson","year":"1994"},{"key":"10.1016\/j.spen.2015.10.008_bib2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): A clinical and molecular review","volume":"4","author":"Evans","year":"2009","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.spen.2015.10.008_bib3","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.spen.2015.10.008_bib4","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/GIM.0b013e3181ac9a27","article-title":"Neurofibromatosis 2 [Bilateral acoustic neurofibromatosis, central neurofibromatosis, NF2, neurofibromatosis type II]","volume":"11","author":"Evans","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.spen.2015.10.008_bib5","first-page":"393","article-title":"Case of tumours in the skull, dura mater, and brain","volume":"18","author":"Wishart","year":"1822","journal-title":"Edinburgh Med Surg J"},{"key":"10.1016\/j.spen.2015.10.008_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/oxfordjournals.jhered.a103390","article-title":"Hereditary bilateral acoustic tumors","volume":"22","author":"Gardner","year":"1933","journal-title":"J Hered"},{"key":"10.1016\/j.spen.2015.10.008_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archneurpsyc.1940.02280070084004","article-title":"Bilateral acoustic neurofibromas: Further clinical and pathologic data on hereditary deafness and Recklinghausen\u2019s disease","volume":"44","author":"Gardner","year":"1940","journal-title":"Arch Neurol Psychiatry"},{"key":"10.1016\/j.spen.2015.10.008_bib8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jama.1970.03180020067012","article-title":"Bilateral acoustic neuroma in a large kindred","volume":"214","author":"Young","year":"1970","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.spen.2015.10.008_bib9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/322644a0","article-title":"Loss of genes on chromosome 22 in tumorigenesis of human acoustic neuroma","volume":"322","author":"Seizinger","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.spen.2015.10.008_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.spen.2015.10.008_bib11","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.spen.2015.10.008_bib12","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/jmg.29.12.841","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity","volume":"29","author":"Evans","year":"1992","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib13","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1136\/jmg.29.12.847","article-title":"A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling","volume":"29","author":"Evans","year":"1992","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","article-title":"Neurofibromatosis type 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity","volume":"52","author":"Parry","year":"1994","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib15","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3171\/jns.2002.96.2.0223","article-title":"Vestibular schwannoma growth in patients with neurofibromatosis type 2: A longitudinal study","volume":"96","author":"Mautner","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.spen.2015.10.008_bib16","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0002-9394(14)72210-X","article-title":"Ocular abnormalities in neurofibromatosis 2","volume":"120","author":"Ragge","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.spen.2015.10.008_bib17","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1001\/archderm.1997.03890480059008","article-title":"Skin abnormalities in neurofibromatosis type 2","volume":"133","author":"Mautner","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.spen.2015.10.008_bib18","first-page":"A133","article-title":"Neurofibromatosis 2 (NF2): Clinical heterogeneity and natural history based on 39 individuals in 9 families and 16 sporadic cases","volume":"49","author":"Eldrige","year":"1991","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s003810050398","article-title":"The different forms of neurofibromatosis","volume":"15","author":"Ruggieri","year":"1999","journal-title":"Child\u2019s Nerv Syst"},{"key":"10.1016\/j.spen.2015.10.008_bib20","first-page":"92","article-title":"Neurofibromatosis type 2 in the paediatric age group","volume":"33","author":"Mautner","year":"1993","journal-title":"Neurosurgery"},{"key":"10.1016\/j.spen.2015.10.008_bib21","first-page":"A576","article-title":"The natural history of neurofibromatosis 2 in 31 affected children","volume":"44","author":"MacCollin","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.spen.2015.10.008_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1071-9091(98)80003-X","article-title":"The diagnosis and management of neurofibromatosis type 2 in childhood","volume":"5","author":"MacCollin","year":"1998","journal-title":"Semin Pediatr Neurol"},{"key":"10.1016\/j.spen.2015.10.008_bib23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/adc.81.6.496","article-title":"Paediatric presentation of type 2 neurofibromatosis","volume":"81","author":"Evans","year":"1999","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.spen.2015.10.008_bib24","first-page":"A66","article-title":"Clinical presentations of neurofibromatosis type 2 in childhood","volume":"3","author":"Ruggieri","year":"1999","journal-title":"Eur J Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.spen.2015.10.008_bib25","first-page":"S6926","article-title":"The various presentations of neurofibromatosis type 2 (NF2) in childhood","volume":"36","author":"Huson","year":"1999","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.spen.2015.10.008_bib26","first-page":"356","article-title":"Neurofibromatosis type 2 (NF2) in childhood","volume":"21","author":"Ruggieri","year":"2000","journal-title":"Neurol Sci"},{"key":"10.1016\/j.spen.2015.10.008_bib27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/08830738030180101301","article-title":"Neurofibromatosis type 1 in the pediatric population","volume":"18","author":"Nunes","year":"2002","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2015.10.008_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1055\/s-2005-837581","article-title":"Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: A study of 24 patients","volume":"36","author":"Ruggieri","year":"2005","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.spen.2015.10.008_bib29","first-page":"489","article-title":"Central nervous system meningiomas in the first two decades of life: A clinicopathological analysis of 87 patients","volume":"103","author":"Rushing","year":"2005","journal-title":"J Neurosurg"},{"key":"10.1016\/j.spen.2015.10.008_bib30","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.ajo.2005.12.042","article-title":"Ophthalmologic findings and long-term course in patients with neurofibromatosis type 2","volume":"141","author":"Bosch","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.spen.2015.10.008_bib31","first-page":"457","article-title":"Neurofibromatosi type 2. A study of 7 patients","volume":"24","author":"Pascual-Castroviejo","year":"2009","journal-title":"Neurologia"},{"key":"10.1016\/j.spen.2015.10.008_bib32","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.braindev.2013.01.007","article-title":"Characterization of early onset neurofibromatosis type 2","volume":"36","author":"Matsuo","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.spen.2015.10.008_bib33","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3171\/2014.3.PEDS13455","article-title":"Clinical course of vestibular schwannoma in pediatric neurofibromatosis type 2","volume":"13","author":"Choi","year":"2014","journal-title":"J Neurosurg Pediatr"},{"key":"10.1016\/j.spen.2015.10.008_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10048-013-0354-0","article-title":"Natural history of neurofibromatosis type 2 with onset before the age of 1 year","volume":"14","author":"Ruggieri","year":"2013","journal-title":"Neurogenetics"},{"key":"10.1016\/j.spen.2015.10.008_bib35","first-page":"314","article-title":"Mutational analysis of patients with neurofibromatosis 2","volume":"55","author":"MacCollin","year":"1994","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib36","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/BF02265270","article-title":"A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2","volume":"97","author":"Kluwe","year":"1996","journal-title":"Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib37","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1093\/hmg\/7.13.2051","article-title":"Mosaicism in sporadic neurofibromatosis 2 patients","volume":"7","author":"Kluwe","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib38","first-page":"727","article-title":"Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis","volume":"63","author":"Evans","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib39","first-page":"89","article-title":"The neurofibromatoses: An overview","volume":"20","author":"Ruggieri","year":"1999","journal-title":"Neurol Sci"},{"key":"10.1016\/j.spen.2015.10.008_bib40","first-page":"530","article-title":"Segmental neurofibromatosis","volume":"93","author":"Ruggieri","year":"2000","journal-title":"J Neurosurg"},{"key":"10.1016\/j.spen.2015.10.008_bib41","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/ajmg.1332","article-title":"Mosaic (segmental) neurofibromatosis type 1 (NF1) and type 2 (NF2)\u2014no longer neurofibromatosis type 5","volume":"101","author":"Ruggieri","year":"2001","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib42","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1212\/WNL.56.11.1433","article-title":"The clinical and diagnostic implications of mosaicism in the neurofibromatosis","volume":"56","author":"Ruggieri","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jmg.40.2.109","article-title":"Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas","volume":"40","author":"Kluwe","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib44","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jmg.2006.047753","article-title":"Mosaicism in neurofibromatosis type 2: An update of risk based on uni\/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification","volume":"44","author":"Evans","year":"2007","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib45","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3171\/JNS\/2008\/108\/01\/0092","article-title":"What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors","volume":"108","author":"Evans","year":"2008","journal-title":"J Neurosurg"},{"key":"10.1016\/j.spen.2015.10.008_bib46","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/jmg.2009.070342","article-title":"An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2)","volume":"46","author":"Evans","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib47","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/cge.12007","article-title":"Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity","volume":"83","author":"Evans","year":"2013","journal-title":"Clin Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib48","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1136\/jmedgenet-2014-102973","article-title":"Manchester NF2 service. Bilateral vestibular schwannomas in older patients: NF2 or chance?","volume":"52","author":"Evans","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib49","first-page":"653","article-title":"Neurofibromatosis","volume":"15","author":"Niimura","year":"1973","journal-title":"Rinsho Derma"},{"issue":"33","key":"10.1016\/j.spen.2015.10.008_bib50","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1086\/301633","article-title":"Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis","volume":"61","author":"Jacoby","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib51","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1212\/WNL.54.1.71","article-title":"Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas","volume":"54","author":"Antinheimo","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib52","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1212\/01.WNL.0000163982.78900.AD","article-title":"Diagnostic criteria for schwannomatosis","volume":"64","author":"MacCollin","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib53","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.46.4.1072","article-title":"Schwannomatosis: A clinical and pathologic study","volume":"46","author":"MacCollin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib54","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/01.wnl.0000201190.89751.41","article-title":"Increasing the specificity of diagnostic criteria for schwannomatosis","volume":"66","author":"Baser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib55","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajmg.a.34376","article-title":"Vestibular schwannomas occur in schwannomatosis and should not be considered an exclusion criterion for clinical diagnosis","volume":"158A","author":"Smith","year":"2012","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.spen.2015.10.008_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/ajmg.a.35760","article-title":"Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria","volume":"161A","author":"Plotkin","year":"2013","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.spen.2015.10.008_bib57","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1086\/513207","article-title":"Germline mutation of INI1\/SMARCB1 in familial schwannomatosis","volume":"80","author":"Hulsebos","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib58","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/humu.20679","article-title":"Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas","volume":"29","author":"Sestini","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.spen.2015.10.008_bib59","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/jmg.2007.056499","article-title":"Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis","volume":"45","author":"Hadfield","year":"2008","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib60","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/ng.2855","article-title":"Germline loss-of-function mutations in LZTR1 predispose to an inherited disorder of multiple schwannomas","volume":"46","author":"Piotrowski","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib61","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/ejhg.2014.220","article-title":"Expanding the mutational spectrum of LZTR1 in schwannomatosis","volume":"23","author":"Paganini","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1212\/WNL.0000000000001129","article-title":"Mutations in LZTR1 add to the complex heterogeneity of schwannomatosis","volume":"84","author":"Smith","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib63","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12920-015-0076-2","article-title":"NF2 multidisciplinary clinics HUGTiP-ICO-IMPPC. Segmental neurofibromatosis type 2: Discriminating two hit from four hit in a patient presenting multiple schwannomas confined to one limb","volume":"8","author":"Castellanos","year":"2015","journal-title":"MC Med Genomics"},{"key":"10.1016\/j.spen.2015.10.008_bib64","doi-asserted-by":"crossref","unstructured":"National Institutes of Health Consensus Development Conference Statement. Neurofibromatosis. Arch Neurol 1988; 45:575-578.","DOI":"10.1001\/archneur.1988.00520290115023"},{"key":"10.1016\/j.spen.2015.10.008_bib65","doi-asserted-by":"crossref","first-page":"39","DOI":"10.7326\/0003-4819-113-1-39","article-title":"NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis) An update","volume":"113","author":"Mulvihill","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.spen.2015.10.008_bib66","first-page":"603","article-title":"A clinical study of type 2 neurofibromatosis","volume":"304","author":"Evans","year":"1992","journal-title":"Q J Med"},{"key":"10.1016\/j.spen.2015.10.008_bib67","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2","volume":"278","author":"Gutmann","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.spen.2015.10.008_bib68","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1212\/01.WNL.0000035638.74084.F4","article-title":"Evaluation of clinical diagnostic criteria for neurofibromatosis 2","volume":"59","author":"Baser","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.spen.2015.10.008_bib69","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/GIM.0b013e318211faa9","article-title":"Empirical development of improved diagnostic criteria for neurofibromatosis 2","volume":"13","author":"Baser","year":"2011","journal-title":"Genet Med"},{"key":"10.1016\/j.spen.2015.10.008_bib70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/jmedgenet-2015-103050","article-title":"Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2","volume":"52","author":"Stivaros","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib71","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.bjc.6604002","article-title":"Nf2\/Merlin: A coordinator of receptor signalling and intercellular contact","volume":"98","author":"Curto","year":"2008","journal-title":"Brit J Cancer"},{"key":"10.1016\/j.spen.2015.10.008_bib72","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1399-0004.2009.01315.x","article-title":"Further genotype-phenotype correlations in neurofibromatosis type 2","volume":"77","author":"Selvanathan","year":"2010","journal-title":"Clin Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib73","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/jmg.2010.085241","article-title":"Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset","volume":"48","author":"Smith","year":"2011","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib74","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1136\/jmg.35.6.450","article-title":"Genotype phenotype correlations in NF2","volume":"35","author":"Evans","year":"1998","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib75","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1136\/jmg.2004.029504","article-title":"The location of constitutional neurofibromatosis 2 (NF2) splice-site mutations is associated with the severity of NF2","volume":"42","author":"Baser","year":"2005","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jmedgenet-2015-103290","article-title":"Clinical and molecular predictors of mortality in neurofibromatosis 2: A UK national analysis of 1192 patients","volume":"52","author":"Hexter","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib77","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","article-title":"Predictors of the risk of mortality in neurofibromatosis 2","volume":"71","author":"Baser","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib78","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3171\/jns.2002.96.6.1063","article-title":"Multichannel auditory brainstem implant: Update on performance in 61 patients","volume":"96","author":"Otto","year":"2002","journal-title":"J Neurosurg"},{"key":"10.1016\/j.spen.2015.10.008_bib79","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1177\/08830738030180101301","article-title":"Neurofibromatosis 2 in the pediatric population","volume":"18","author":"Nunes","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.spen.2015.10.008_bib80","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/MAO.0000000000000185","article-title":"Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2","volume":"35","author":"Lloyd","year":"2014","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.spen.2015.10.008_bib81","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/jmg.2005.036319","article-title":"Malignant transformation and new primary tumours after therapeutic radiation for benign disease: Substantial risks in certain tumour-prone syndromes","volume":"43","author":"Evans","year":"2006","journal-title":"J Med Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib82","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1399-0004.2011.01816.x","article-title":"Genetic testing and screening of individuals at risk of NF2","volume":"82","author":"Evans","year":"2012","journal-title":"Clin Genet"},{"key":"10.1016\/j.spen.2015.10.008_bib83","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1517\/13543784.2013.772979","article-title":"Optimizing biologically targeted clinical trials for neurofibromatosis","volume":"22","author":"Gutmann","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.spen.2015.10.008_bib84","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ctrv.2014.05.004","article-title":"Systemic therapy in neurofibromatosis type 2","volume":"40","author":"Lim","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.spen.2015.10.008_bib85","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/MAO.0b013e31817f7398","article-title":"The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: A preliminary study","volume":"29","author":"Clark","year":"2008","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.spen.2015.10.008_bib86","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ncponc1157","article-title":"Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy","volume":"5","author":"Plotkin","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.spen.2015.10.008_bib87","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.spen.2015.10.008_bib88","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","article-title":"Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients","volume":"31","author":"Plotkin","year":"2010","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.spen.2015.10.008_bib89","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1200\/JCO.2011.38.2614","article-title":"Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: From bench to bedside","volume":"30","author":"Subbiah","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.spen.2015.10.008_bib90","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.spen.2015.10.008_bib91","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nrneurol.2011.82","article-title":"Emerging therapeutic targets in schwannomas and other merlin-deficient tumors","volume":"7","author":"Ammoun","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.spen.2015.10.008_bib92","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.ejca.2009.03.013","article-title":"Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells","volume":"45","author":"Lee","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.spen.2015.10.008_bib93","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate)","volume":"69","author":"Mukherjee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.spen.2015.10.008_bib94","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nor056","article-title":"Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2","volume":"13","author":"Ammoun","year":"2011","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.spen.2015.10.008_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-010274","article-title":"Imatinib in neurofibromatosis type 2","author":"Lim","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.spen.2015.10.008_bib96","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.spen.2015.10.008_bib97","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.spen.2015.10.008_bib98","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","article-title":"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: A retrospective review of 31 patients","volume":"33","author":"Plotkin","year":"2012","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.spen.2015.10.008_bib99","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","article-title":"Bevacizumab treatment for meningiomas in NF2: A retrospective analysis of 15 patients","volume":"8","author":"Nunes","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.spen.2015.10.008_bib100","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1055\/s-0033-1336173","article-title":"Antiangiogenic agents for nonmalignant brain tumors","volume":"74","author":"Hawasli","year":"2013","journal-title":"J Neurol Surg B Skull Base"},{"key":"10.1016\/j.spen.2015.10.008_bib101","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","article-title":"The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2","volume":"272","author":"Alanin","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.spen.2015.10.008_bib102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-015-1828-8","article-title":"Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2","volume":"124","author":"Hochart","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.spen.2015.10.008_bib103","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1007\/s00405-015-3604-y","article-title":"Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"272","author":"Farschtschi","year":"2015","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"10.1016\/j.spen.2015.10.008_bib104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.spen.2015.10.008_bib105","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","article-title":"Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: Report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy","volume":"126","author":"Eminowicz","year":"2012","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.spen.2015.10.008_bib106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/159101991201800201","article-title":"Short-term clinico-radiographic response to super-selective intra-arterial cerebral infusion of Bevacizumab for the treatment of vestibular schwannomas in neurofibromatosis type 2","volume":"18","author":"Riina","year":"2012","journal-title":"Interv Neuroradiol"},{"key":"10.1016\/j.spen.2015.10.008_bib107","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3171\/jns.2003.99.3.0480","article-title":"Age at symptom onset and long-term survival in patients with neurofibromatosis type 2","volume":"99","author":"Otsuka","year":"2003","journal-title":"J Neurosurg"}],"container-title":["Seminars in Pediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909115000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071909115000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:36:16Z","timestamp":1761028576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071909115000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1071909115000753"],"URL":"https:\/\/doi.org\/10.1016\/j.spen.2015.10.008","relation":{},"ISSN":["1071-9091"],"issn-type":[{"value":"1071-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Pediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.spen.2015.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}